1. Home
  2. CRNT vs MGNX Comparison

CRNT vs MGNX Comparison

Compare CRNT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ceragon Networks Ltd.

CRNT

Ceragon Networks Ltd.

HOLD

Current Price

$2.51

Market Cap

221.1M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.45

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNT
MGNX
Founded
1996
2000
Country
Israel
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
221.1M
220.6M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
CRNT
MGNX
Price
$2.51
$3.45
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$3.50
$5.00
AVG Volume (30 Days)
491.0K
841.4K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
$9.11
N/A
Revenue Next Year
$6.70
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.82
$1.19
52 Week High
$2.84
$3.88

Technical Indicators

Market Signals
Indicator
CRNT
MGNX
Relative Strength Index (RSI) 50.09 58.33
Support Level $2.22 $1.48
Resistance Level $2.61 $3.88
Average True Range (ATR) 0.13 0.22
MACD -0.01 0.01
Stochastic Oscillator 28.74 58.08

Price Performance

Historical Comparison
CRNT
MGNX

About CRNT Ceragon Networks Ltd.

Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: